key: cord-0013358-tb8qq0tk authors: Sampayo-Cordero, Miguel; Miguel-Huguet, Bernat; Malfettone, Andrea; Pérez-García, José Manuel; Llombart-Cussac, Antonio; Cortés, Javier; Pardo, Almudena; Pérez-López, Jordi title: The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II) date: 2020-09-10 journal: Int J Environ Res Public Health DOI: 10.3390/ijerph17186590 sha: 2b90456e5de5e81b77ebb447e051b2cd020e2f82 doc_id: 13358 cord_uid: tb8qq0tk Background: Case reports are usually excluded from systematic reviews. Patients with rare diseases are more dependent on novel individualized strategies than patients with common diseases. We reviewed and summarized the novelties reported by case reports in mucopolysaccharidosis type II (MPS-II) patients treated with enzyme replacement therapy (ERT). Methods: We selected the case reports included in a previous meta-analysis of patients with MPS-II treated with ERT. Later clinical studies evaluating the same topic of those case reports were reported. Our primary aim was to summarize novelties reported in previous case reports. Secondary objectives analyzed the number of novelties evaluated in subsequent clinical studies and the time elapsed between the publication of the case report to the publication of the clinical study. Results: We identified 11 innovative proposals in case reports that had not been previously considered in clinical studies. Only two (18.2%) were analyzed in subsequent nonrandomized cohort studies. The other nine novelties (81.8%) were analyzed in later case reports (five) or were not included in ulterior studies (four) after more than five years from their first publication. Conclusions: Case reports should be included in systematic reviews of rare disease to obtain a comprehensive summary of the state of research and offer valuable information for healthcare practitioners. Rare diseases and ultra-rare diseases are defined by a prevalence of ≤50 patients and ≤1 patient per 100,000 people, respectively. This low prevalence of such diseases makes the conduction of randomized and prospectively designed studies very hard [1, 2] . As an example, mucopolysaccharidosis type II (MPS-II) has a prevalence of 1 in 140,000-156,000 patients [3] . In this case, the registries of clinical cases usually are the best option for clinical research [4, 5] . Furthermore, in rare diseases, the phenotype and genotype heterogeneity limit the generalization of the data from clinical trials to clinical practice [1, 6] . Thus, pharmacological treatment of patients with orphan and ultra-orphan drugs is more dependent on individualized strategies than treatment of more prevalent diseases [7, 8] . The value of case reports as individual studies has been stated in previous reviews [9] . Investigators have considered that case reports are appropriate to report new clinical findings, generating new hypothesis about pharmacological therapies, educational value, and high applicability in situations where other designs are not feasible. However, case reports are limited by their retrospective, nonblinded, and nonrandomized trial design, constituting a source of biases that could affect the study outcome. Therefore, findings provided by case reports might not be generalizable and could not be useful to establish a cause-effect relationship, with a consequent high risk of over-interpretation [9] [10] [11] . Accordingly, it is uncommon to include case reports in systematic reviews and meta-analyses [12, 13] . Systematic reviews were developed to ensure that decisions affecting human health would be informed with the complete understanding of the most relevant research evidence. Thus, the purpose of a systematic review is to provide a summary of the state of research knowledge on an intervention, diagnostic test, prognostic factor, or other health or healthcare topics [12] . It has been suggested that novelties about available interventions are published in case reports five or more years earlier than in clinical studies [13] . Accordingly, a detailed review of a health topic should not exclude published clinical reports, especially in the field of rare diseases, where the individualization of treatments or management strategies has a great relevance on clinical practice [14, 15] . A systematic review evaluating the efficacy and safety of enzyme replacement therapy (ERT) for treatment of patients with MPS-II has been previously published [2] . The aim of the present study was to review the novelties on outcomes or therapeutic strategies reported in case studies of the mentioned systematic review [2] . Secondary objectives included the number of novelties evaluated in subsequent clinical studies and the time elapsed between the publication of a novelty in a case report and its subsequent inclusion in a clinical study. Consequently, we searched for the latest clinical studies that incorporated the research questions stated by previous case reports. The case reports selected were previously included in a recent meta-analysis by Sampayo-Cordero M. et al. [2] . The systematic review included case reports of MPS-II patients who were treated with ERT, and the search was carried out in Excerpta Medica Database (EMBASE), Medical Literature Analysis and Retrieval System Online (MEDLINE), The Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, and Cochrane Methodology Register and Health Technology Assessment Databases), as well as on the Latin American and Caribbean Literature on Health Sciences (LILACS). The search methods, study selection, and quality assessment are deeply described in the mentioned publication [2] . All case reports published up to 31 December 2015 were included in the search. For the current study, we selected all case reports that evaluated a new outcome or a new therapeutic strategy with ERT in MPS-II patients. Case reports excluded objectives that were similar to those described in previous randomized and nonrandomized studies [16] [17] [18] [19] [20] . The case reports selected from the previous meta-analysis were used to search new clinical studies with the same issue. We searched for the most recent clinical studies that incorporated the novelties proposed by case reports in patients with MPS-II treated with ERT. We searched MEDLINE and GOOGLE (all) for case reports that reported these novelties and retrieved the citations included in sections "cited by" or "comment". There was no restriction of dose, treatment duration, administration via (intravenous or intrathecal), type of study design, or language. All published studies up to 1 July 2020 were included in our comprehensive search. We selected all clinical studies citing the original case report, which accomplished the following selection criteria: Inclusion criteria: (1) Clinical studies (randomized or nonrandomized) and case reports of patients with MPS-II treated with ERT. (2) The study design evaluates as primary, secondary, or exploratory objective the novelty proposed by the case report. (1) Clinical studies or case reports in other diseases or based on treatment without ERT. (2) Systematic or literature reviews that do not include analyses of new patients. The study was prospectively designed to select the studies that analyzed the novelties proposed by previous case reports on MPS-II. Results of current meta-analysis are reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and Meta-Analyses and Systematic Reviews of Observational Studies (MOOSE) guidelines [21, 22] . Three investigators (M.S.-C., B.M.-H., and A.P) entered findings into a database, independently reviewed citations/abstracts from the database, and hand searched and selected full relevant articles and documents for data extraction using preset criteria. Discrepancies were resolved through discussion or input from a fourth reviewer (J.P.-L.). The primary outcome was a synthetic description of novelties proposed by the case reports that were selected in the meta-analysis of Sampayo-Cordero M. et al. [2] . We compared the objectives and ERT schedules of each selected case report with those of clinical studies published prior to the meta-analysis [16] [17] [18] [19] [20] . The case reports with objectives or therapy strategies equal to those of the clinical studies were not considered. Only the case reports analyzing novel objectives and therapy strategies were described. A. The number of novelties proposed by prior case reports evaluated in subsequent clinical studies. The subsequent clinical studies were reported by type of study (randomized, cohort study, and case report). B. The time between the publication of the case report and the clinical study. Novelties described in each case report were summarized in a narrative format. The number of novelties and clinical studies was reported as number and percentage. The time elapsed between the publication of a case report including a specific novelty and the follow-up clinical study or studies was calculated subtracting the date of the first clinical study to the date of the first case report analyzing such novelty. If there was not a clinical study analyzing that novelty, the cutoff date was 1 July 2020. Novelties described in each case report were summarized in a narrative format. The number of novelties and clinical studies was reported as number and percentage. The time elapsed between the publication of a case report including a specific novelty and the follow-up clinical study or studies was calculated subtracting the date of the first clinical study to the date of the first case report analyzing such novelty. If there was not a clinical study analyzing that novelty, the cutoff date was 1 July 2020. An accurate selection of case reports with novelties published by Sampayo-Cordero et al. [2] , which included publications through 31 December 2015, identified 27 citations [2] . Of 27 studies identified, 11 were excluded because they evaluated objectives and ERT schedules equivalent to those of previous clinical studies [16] [17] [18] [19] [20] . Thus, 16 publications of case reports were included in the study and their summary identified 11 different novelty proposals about ERT in MPS-II patients (primary objective). Searching for these 16 case reports, we identified 72 following publications. However, 11 of 72 publications analyzed the novelties of these case reports, while the remaining 61 publications were excluded because they did not (see Supplementary Table S1 and Figure 1 ). Our study identified 11 innovative proposals in case reports that had not been previously considered in clinical studies. Most of them evaluated the efficacy of ERT in different outcomes and therapeutic situations compared with those included in previous clinical studies. They considered skin lesions, hyperactivity, aggressive behavior, language functioning, social interaction, central nervous system development, epileptogenic symptoms, effects in vision, and bone abnormalities. In addition, some case reports evaluated the efficacy of ERT in patients with physical abnormalities or affected by hematological diseases. Finally, three studies suggested new therapeutic strategies to increase the immunotolerance for ERT and to reduce dermatan sulfate in plasma (see Table 1 ) [23] [24] [25] . [38] ERT-enzyme replacement therapy, MPS-II-mucopolysaccharidosis type II. *-Only case reports reporting novelties were analyzed. Case reports excluded analyzed objectives similar to those described in previous randomized and nonrandomized studies ( Of 11 novelties, only two (18.2%) were analyzed in subsequent cohort studies: (1) The efficacy of early ERT in central nervous system and (2) bone abnormalities. The other nine novelties (81.8%) were analyzed in later case reports (five novelties) or were not included in ulterior studies (four novelties). The five novelties evaluated in new case reports were: (1) The immune tolerance regimen, (2) the effect of ERT in skin, (3) the effect of ERT in epileptogenic symptoms, (4) the effect of ERT in ocular function, and (5) the effect of ERT in hematological diseases. So, novelties proposed in case reports are usually confirmed with later case reports. None of the proposed innovations was included in the objectives of a subsequent randomized clinical trial. In most cases, novel strategies suggested in case reports were not evaluated in a cohort or randomized study after 5 to 12 years (see Table 2 ). Table 2 . Clinical studies evaluating novelties proposed by prior case reports. (1) Immune tolerance regimen and desensitization procedures [23, 24] Case report (Julien DC et al., 2020) [50] No clinical study after 6 years (2) New therapeutic strategies based on the evaluation of plasmatic dermatan sulfate [25] No new citations No clinical study after 7 years (3) Effects in pebbling skin lesions [26, 27] Case report (Srinivas SM et al., 2017) [51] No clinical study after 8 years (4) Effects in hyperactivity, aggressive behavior, language functioning, and social interaction [28] No clinical study after 7 years No clinical study after 7 years [57, 58] No clinical study after 8 years (7) ERT effects in vision [32, 33] Case report (Yamanishi R et al., 2019) [59] No clinical study after 5 years (8) ERT effect in autoimmune anemia, thrombocytopenia, or thrombocytopenic purpura [34, 35] Case report (Alcántara-Ortigoza et al., 2016) [60] No clinical study after 8 years (9) Botulinum Toxin for the treatment of equinus deformity with an ERT [36] No new citations No clinical study after 8 years (10) ERT effects in involuntary movements (chorea) [37] No new citations No prospective study after 12 years (11) Early ERT effects in bone abnormalities [38] Cohort study (Manara R [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . ** This study analyzed two novelties proposed by previous case reports. In the last years, the interest in case reports by clinical research community as well as the number of journals that publish case reports have increased rapidly [61] . Clinical cases' journals have been included in the Medline database for medical journals and registries of case reports have been developed [9] . The greatest advantages of clinical cases are represented by their ability to detect novelties, the generation of new hypotheses, and their usefulness in the investigation of rare diseases [9] . Additionally, the individualization of therapies and management strategies is a key factor to successfully treat patients with rare diseases. So, new proposals dealing with uncommon situations in the treatment of rare-disease patients have great relevance to translate clinical research into clinical practice [7, 8] . One of the aims of systematic reviews on therapeutic interventions is to summarize the state of art in this intervention [12] . However, case reports are systematically excluded in systematic reviews in rare-disease research, especially when other designs with a higher level of evidence are included [12, 15, [62] [63] [64] [65] . Therefore, important innovations, which could contribute to a better management of the patient treated with orphan drugs, are systematically excluded from systematic reviews of rare diseases [2, 13] . Our results on MPS-II patients treated with ERT showed that case reports reported findings relevant to complement patient management. The efficacy of ERT was explored on key outcomes (social behavior, skin lesions, central nervous system development, bone abnormalities, visual acuity) and specific situations (serious respiratory impairment, hematological disease, and physical abnormalities) that had not been considered in previous clinical studies. Additionally, case reports also proposed new therapeutic strategies to deal with immune reactions against ERT [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 49] . In accordance with previous results, we observed that most of these novelties were not assessed in subsequent clinical studies after five years from the publication of the case report [13] . Importantly, the new studies assessing these proposals were usually case reports [31, 50, 51, 57, 59, 60] . Therefore, the evidence and innovations provided by case reports will take a long time to be incorporated into clinical studies on rare diseases [13] . Some previous systematic reviews in MPS have included case reports with clinical studies [2, [13] [14] [15] . As we observed in our results, the inclusion of case reports was necessary to complete the evaluation of the ERT profile in specific situations (pregnancy, ERT discontinuation, surgery interventions, recovering from cerebral infarctions, serious respiratory impairment, or hematological diseases), key alternative outcomes (frequency of respiratory infections, texture of hair and/or skin, skeletal disease, or disease-related hospitalizations), and alternative therapeutic strategies with ERT [2, [13] [14] [15] . Additionally, the inclusion of case reports allows us to assess the heterogeneity between the patients included in clinical studies and those from clinical cases; and it is useful to evaluate if ERT efficacy and safety results are equivalent among different study designs. The inclusion of case reports allows including all available evidence on ERT and it could increase the power of analyses performed [2, [13] [14] [15] . We observed in previous systematic reviews including case reports that they used two alternative strategies. The first proposal summarized the results of the case reports and discussed them qualitatively. The results from case reports were not included in meta-analyses [14, 15] . The second method aggregated the results of case reports in a meta-analysis. The strategy to analyze the results was to define two improvement (or impairment) criteria. One for individual patients included in the meta-analyses (e.g., increase in 6-min walk test over the baseline assessment) and another for the specific outcome or group of patients evaluated (e.g., a significant difference versus a 5% null hypothesis in the rate of patients with improvement in the walk test) [2, 13] . Both methodologies represent an advantage with respect to excluding clinical cases from systematic reviews, since they allow enriching the study's results and conclusions [2, [13] [14] [15] . Importantly, these studies have demonstrated that standardization and a good definition of outcomes evaluated in case reports increase the validity of their results [2, 13] . Therefore, the tools to assess the quality of case reports and case series are very relevant in systematic reviews that include clinical cases [66] . Different efforts have been done to homogenize and upgrade the quality of case reports [67] or to search for case reports in clinical databases [9, 68] . Previous studies and guidelines have considered that clinical cases could be included in systematic reviews [2, 13, 69] . However, they do not consider the exclusion of case reports a serious concern if there are other designs available. Case report exclusion from systematic reviews in rare diseases has a greater impact than just the loss of a few cases with rare conditions or rare adverse events [12, 69] . In fact, our analyses show that most of the novelties proposed in case reports are not subsequently contrasted in clinical studies with more patients (after 5 to 12 years), which might be due to the case reports being overlooked, since they are not included in reviews. Our study took advantage of a previous systematic review to select the individual case reports analyzed in this communication. We considered that this strategy provides an important quality control measure. The selection procedures was previously accepted after a peer review revision [2] . An important point in our strategy for data search was retrieving articles, which cited selected case reports. Some articles could have analyzed novelty of a case report without citing it. However, in rare diseases, and in MPS-II disease specifically, the number of clinical studies is quite limited, so it is not likely to happen in many communications [62] . In addition, our study only included case reports from MPS-II patients. Therefore, it is not clear whether the results obtained in this study could be extrapolated to other rare diseases, although it is important to note that the methods for aggregating clinical cases obtained similar results in different MPS, namely MPS-I and MPS-II [2, [13] [14] [15] . It is usually considered that a MEDLINE search alone is not adequate for answering relevant questions [12] . In accordance, we have increased the scope of our search with GOOGLE searcher, since it is commonly used in all types of searches and has specific tools for systematic reviews and scientific searches [70, 71] . Different authors have underlined the impact of individual clinical reports' results in clinical practice and research [11, 72] . Previous studies and guidelines have suggested the inclusion of case reports in systematic reviews, but they did not consider the exclusion of case reports a serious concern if there are other designs available with a higher grade of evidence than case reports [12, 69] . However, according to our results, most of the novel procedures proposed in case reports are not evaluated in later clinical studies. Thus, case reports should be included in systematic reviews of rare diseases to make a complete summary of the state of research, since excluding relevant novelties proposed in case reports could reduce the usefulness of the review for clinical practice. Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease Ten years of the Hunter Outcome Survey (HOS): Insights, achievements, and lessons learned from a global patient registry Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS) Evidence for Health Decision Making-Beyond Randomized Critical clinical situations in adult patients with Mucopolysaccharidoses (MPS) Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program The clinical case report: A review of its merits and limitations Aggregating case reports: A way for the future of evidence-based health care? Clin. Case Rep Important of case-reports/series, in rare diseases: Using neuroendocrine tumors as an example Cochrane Handbook for Systematic Reviews of Interventions|Cochrane Training Agreement between the results of meta-analyses from case reports and from clinical studies regarding the efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age: An example of case reports meta-analyses as an useful tool for evidence-based medicine in rare diseases Moltó-Abad, M. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome Improved Metabolic Correction in Patients with Lysosomal Storage Disease Treated with Hematopoietic Stem Cell Transplant Compared with Enzyme Replacement Therapy Enzyme Replacement is Associated with Better Cognitive Outcomes after Transplant in Hurler Syndrome The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report Case of infusion reaction to idursulafase and successful re-administration with desensitization. Poster Session Group III-Green TPS 39 Plasmatic kinetics of dermatan sulfate during enzyme replacement therapy with iduronate-2-sulfatase in a mucopolysaccharidosis II Patient Characteristic "pebbling" skin eruption as a presenting sign of Hunter syndrome Hunter Syndrome: Resolution of Extensive Typical Skin Lesions After 9 Months of Enzyme Replacement Therapy with Idursulfase Hunter syndrome follow-up after 1 year of enzyme-replacement therapy Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II EEG Evaluation of Mucopolysaccharidosis Type II After Enzyme Replacement Therapy Non-convulsive status epilepticus of frontal origin in mucopolysaccharidosis type II successfully treated with ethosuximide: Case Report Role of SD-OCT in the follow-up of a patient with macular edema associated with mucopoysaccharidosis type II (Hunter syndrome) undergoing idursulfase enzyme replacement therapy Multiple mechanisms of ophthalmologic involvement in attenuated Hunter syndrome: A case report Autoimmune thrombocytopenia in a patient with hunter syndrome: Should iduronate-2-sulfatase replacement therapy still be considered? Pediatr Hunter syndrome and new onset idiopathic thrombocytopenic purpura in a young patient Botulinum Toxin Type A for the Treatment of Equinus Deformity in Patients with Mucopolysaccharidosis Type II A novel mutation in the iduronate 2 sulfatase gene resulting in mucopolysaccharidosis type II and chorea: Case report of two siblings Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome) Mucopolysaccharidosis II Patients Under 1 Year of Age Mucopolysaccharidosis type II (MPS II): Case report of three affected siblings Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene Massive Accumulation of Glycosaminoglycans in the Aortic Valve of a Patient with Hunter Syndrome During Enzyme Replacement Therapy Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: Comparison in two siblings Hunter Disease Before and During Enzyme Replacement Therapy Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: A 3-year follow-up: Enzyme replacement therapy for mucopolysaccharidosis II Respuesta precoz a idursulfasa en un paciente de 31 años de edad con síndrome de Hunter Three Adult Siblings with Mucopolysaccharidosis Type II (Hunter Syndrome): A Report on Clinical Heterogeneity and 12 Months of Therapy with Idursulfase Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome Successful Noninvasive Ventilation and Enzyme Replacement Therapy in an Adult Patient with Morbus Hunter Immune Modulation for Enzyme Replacement Therapy in A Pebbling of skin: Cutaneous marker of Hunter syndrome Cerebral magnetic resonance findings during enzyme replacement therapy in mucopolysaccharidosis Brain and spine MRI features of Hunter disease: Frequency, natural evolution and response to therapy Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II Cognitive and behaviour profiles of children with mucopolysaccharidosis Type II Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: A nationwide survey in Japan Epilepsy in mucopolysaccharidosis disorders Nocturnal frontal lobe epilepsy in mucopolysaccharidosis Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II Wide allelic heterogeneity with predominance of large IDS gene complex rearrangements in a sample of Mexican patients with Hunter syndrome: Mutational spectrum in a sample of Mexican MPSII patients The recent history of the clinical case report: A narrative review Treatment of mucopolysaccharidosis type II (Hunter syndrome): Results from a systematic evidence review Eficácia e segurança da terapia com idursulfase em pacientes com mucopolissacaridose tipo II, com e sem comparação com placebo: Revisão sistemática e metanálise Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome) Safety of Enzyme Replacement Therapy for Mucopolysaccharidosis II Methodological quality and synthesis of case series and case reports The CARE Group The CARE guidelines: Consensus-based clinical case reporting guideline development Identifying main finding sentences in clinical case reports Batel Marques, F. A comparison between two recommendations to conduct and report systematic reviews on drug's safety Google Search as an Additional Source in Systematic Reviews Systematic Review of Clinical Insights into Novel Coronavirus (CoVID-19) Pandemic: Persisting Challenges in U.S. Rural Population Medical case reports in the age of genomic medicine Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future Therapeutic options for mucopolysaccharidoses: current and emerging treatments Recommendations for the management of MPS IVA: Systematic evidence-and consensus-based guidance Innovative Treatments for Mucopolysaccharidoses Current and Emerging Therapies for Mucopolysaccharidoses Handbook of Experimental Pharmacology Spectrum of lysosomal storage disorders at tertiary centre: Retrospective case-record analysis Hamartomas of skin and soft tissue Current and emerging management options for patients with Morquio A syndrome Therapy for the mucopolysaccharidoses Diagnosis and treatment trends in mucopolysaccharidosis I: Findings from the MPS I Registry Brain and Spinal MR imaging findings in mucopolysaccharidoses: A review Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: Translating success in animal models to patients Neuroimaging findings in patients with mucopolysaccharidosis: What you really need to know Imaging nanifestations of the leukodystrophies, inherited disorders of white matter Duat Rodríguez, A. Neuroimaging findings in patient series with mucopolysaccharidosis Effect of 6 years of enzyme replacement therapy on plasma and urine glycosaminoglycans in attenuated MPS I patients Retroviral-vector-mediated gene therapy to mucopolysaccharidosis I mice improves sensorimotor impairments and other behavioral deficits Lysosomal Disorders associated with leukoencephalopathy Lysosomal enzymes may cross the blood-brain-barrier by pinocytosis: Implications for Enzyme Replacement Therapy Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1 Fucosidosis in a domestic shorthair cat High-dose enzyme replacement therapy attenuates cerebroventriculomegaly in a mouse model of mucopolysaccharidosis type II Skeletal Dysplasias: Growing Therapy for Growing Bones Guía de práctica clínica para el tratamiento del síndrome de Hunter A novel, long-lived, and highly engraftable immunodeficient mouse model of mucopolysaccharidosis type I Mucopolysaccharidoses: Overview of neuroimaging manifestations Regression of ventriculomegaly following medical management of a patient with Hurler syndrome Ocular Manifestations of Inborn Errors of Metabolism Characterization of a Mucopolysaccharidosis Type I and GalNAc Transferase Deficiency Double Knockout Mouse Enzyme replacement therapy in lysosomal storage diseases Advances in Predictive, Preventive and Personalised Medicine Diagnosis and Therapies for Mucopolysaccharidoses. Doctoral Dissertation Quantitative determination of urinary mucopolysaccharide and its clinical application. Chin. J. Children's Health Analysis of clinical features of mucopolysaccharidosis type II The role of prenatal fetal heart monitoring in reducing fetal and neonatal injury Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: Results of a consensus procedure Cognitive and adaptive measurement endpoints for clinical trials in mucopolysaccharidoses types I, II, and III: A review of the literature The 'Photosensitivity Model' is ( also) a model for focal (partial) seizures Rebuttal to the manuscript by Ethosuximid bei strukturellen und läsionellen Epilepsien Coinvolgimento neurologico nelle MPS. La Rivista delle Malattie Rare The photosensitivity model is not a model for partial (focal) seizures-REBUTTAL Clinical analysis of status epilepticus secondary to acute cerebral hemorrhage Segmentation of diabetic macular edema for retinal OCT images Evaluation of hematologic findings in mucopolysaccharidosis cases Hunter syndrome with persistent thrombocytopenia The modern view of mucopolysaccharidosis type II in children: a multidisciplinary approach to the problem Hal) Scoping review of symptoms in children with rare, progressive, life-threatening disorders Identification of a novel mutation of IDS gene from a Chinese pedigree with MPS II Glycosaminoglycan storage disorders: A review Current and potential therapeutic strategies for mucopolysaccharidoses Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS Cervical Spine MRI Findings in Patients with Mucopolysaccharidosis Type II The Effects of Undegraded Glycosaminoglycans from Mucopolysaccharidoses on Osteoblast Differentiation and Mineralisation In Vitro The authors thank Albiotech consultores S.L. for medical writing. The authors thank the reviewers for their positive comments and careful review, which helped improve the manuscript.